Dolutegravir intermediate-1
Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV) -1 infection.
Product Specifications
CAS Number
[1335210-23-5]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HIV
Type
Reference compound
Related Pathways
Anti-infection
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/Dolutegravir_intermediate-1.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=C(OC)C(C(C(O)=O)=CN1CC(OC)OC)=O)OC
Molecular Formula
C13H17NO8
Molecular Weight
315.28
Precautions
H302, H315, H319, H335
References & Citations
[1]Sivaram Prasad, et al. Process for the preparation of dolutegravir . WO 2016125192 A2.
Shipping Conditions
Room Temperature
Storage Conditions
Store at room temperature, keep dry and cool
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HIV-1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
COT, phosphorylated (Thr290) (Cancer Osaka Thyroid Oncogene, c-COT, EST, ESTF, Mitogen-activated Protein Kinase Kinase Kinase 8, MAP3K8, MEKK8, Proto-oncogene c-Cot, Serine/threonine-protein Kinase Cot, Tumor Progression Locus 2, TPL2, TPL-2) (MaxLight 550) discontinued
